EditorialKommentarOpen Access
Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma
Oncotarget · 2023
DOI: 10.18632/oncotarget.28441 ↗Kurz gefasst
Editorial in der Zeitschrift Oncotarget, 2023. Verfasst von Silvia Pietrobono und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Transcription Factors, Melanoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Transcription FactorsMelanomaHumansHedgehog ProteinsNuclear ProteinsSignal TransductionZinc Finger Protein GLI1Cell Line, TumorCell ProliferationCell Cycle ProteinsBromodomain Containing Proteins
Stichwörter der Autor:innen
BRD4GLI1SOX2hedgehog signalingmelanoma
Substanzen
Transcription FactorsHedgehog ProteinsNuclear ProteinsZinc Finger Protein GLI1Cell Cycle ProteinsBRD4 protein, humanBromodomain Containing Proteins
Zitieren
APA
Pietrobono, S., & Stecca, B. (2023). Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma. Oncotarget. https://doi.org/10.18632/oncotarget.28441
Vancouver
Pietrobono S, Stecca B. Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma. Oncotarget. 2023. doi:10.18632/oncotarget.28441
BibTeX
@article{Pietrobono2023,
author = {Pietrobono, Silvia and Stecca, Barbara},
title = {Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma},
journal = {Oncotarget},
year = {2023},
doi = {10.18632/oncotarget.28441}
}
EUVIMED